Treatment for periodic paralysis (Review)

Sansone V, Meola G, Links T, Panzeri M, Rose MR

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2008, Issue 3

http://www.thecochranelibrary.com

WILEY Publishers Since 1807

Treatment for periodic paralysis (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
<table>
<thead>
<tr>
<th>TABLE OF CONTENTS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>HEADER</td>
<td>1</td>
</tr>
<tr>
<td>ABSTRACT</td>
<td>1</td>
</tr>
<tr>
<td>PLAIN LANGUAGE SUMMARY</td>
<td>2</td>
</tr>
<tr>
<td>BACKGROUND</td>
<td>2</td>
</tr>
<tr>
<td>OBJECTIVES</td>
<td>3</td>
</tr>
<tr>
<td>METHODS</td>
<td>3</td>
</tr>
<tr>
<td>RESULTS</td>
<td>4</td>
</tr>
<tr>
<td>DISCUSSION</td>
<td>6</td>
</tr>
<tr>
<td>AUTHORS’ CONCLUSIONS</td>
<td>7</td>
</tr>
<tr>
<td>ACKNOWLEDGEMENTS</td>
<td>7</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>8</td>
</tr>
<tr>
<td>CHARACTERISTICS OF STUDIES</td>
<td>10</td>
</tr>
<tr>
<td>DATA AND ANALYSES</td>
<td>14</td>
</tr>
<tr>
<td>Analysis 1.1. Comparison 1 Comparison between HypoPP and HyperPP attack rate per week on DCP relative to placebo,</td>
<td>14</td>
</tr>
<tr>
<td>Outcome 1 Mean improvement in attack rate per week on DCP relative to placebo.</td>
<td>14</td>
</tr>
<tr>
<td>Analysis 1.2. Comparison 1 Comparison between HypoPP and HyperPP attack rate per week on DCP relative to placebo,</td>
<td>15</td>
</tr>
<tr>
<td>Outcome 2 Mean improvement in severity-weighted attack rate per week on DCP relative to placebo.</td>
<td>15</td>
</tr>
<tr>
<td>ADDITIONAL TABLES</td>
<td>15</td>
</tr>
<tr>
<td>APPENDICES</td>
<td>17</td>
</tr>
<tr>
<td>WHAT’S NEW</td>
<td>19</td>
</tr>
<tr>
<td>HISTORY</td>
<td>19</td>
</tr>
<tr>
<td>CONTRIBUTIONS OF AUTHORS</td>
<td>19</td>
</tr>
<tr>
<td>DECLARATIONS OF INTEREST</td>
<td>19</td>
</tr>
<tr>
<td>INDEX TERMS</td>
<td>20</td>
</tr>
</tbody>
</table>
ABSTRACT

Background
Primary periodic paralyses are rare inherited muscle diseases characterised by episodes of flaccid weakness affecting one or more limbs, lasting several hours to several days, caused by mutations in skeletal muscle channel genes.

Objectives
The objective of this review was to systematically review treatment of periodic paralyses.

Search methods
We searched the Cochrane Neuromuscular Disease Group Trials Register, MEDLINE (from January 1966 to July 2007), and EMBASE (from January 1980 to July 2007) and any other available international medical library sources from the University of Milan for randomised trials.

Selection criteria
We included randomised (including cross-over studies) and quasi-randomised trials in participants with primary periodic paralyses, in which any form of treatment, including physical therapy and alternative therapies, was compared to placebo or another treatment.

Data collection and analysis
Our primary outcome measure was the change in attack severity or frequency by eight weeks from the start of treatment.

Our secondary outcome measures were: change in muscle strength and mass; change in Quality of Life, using Short Form 36 (SF36) or similar; preference of treatment strategy; adverse effects at eight weeks.

Main results
Three studies met our inclusion criteria. In one study dichlorphenamide (DCP) vs placebo was tested in two groups of participants: 42 with hypokalemic periodic paralysis (HypoPP) and 31 with hyperkalemic periodic paralysis (HyperPP), based on clinical criteria. Thirty-four of 42 participants with hypokalemic periodic paralysis completed both treatment phases. For the 34 participants having attack rate data for both treatment phases, the mean improvement in attack rate (P = 0.02) and severity-weighted attack rate (P = 0.01) on DCP relative to placebo were statistically significant. Fifteen preferred DCP, three placebo and six their baseline medication.
Twenty-four of 31 participants with hyperkalemic periodic paralysis completed both treatment phases: for the 16 participants who had attack rate data for both treatment phases, the mean improvement in attack rate (P = 0.006) and in severity-weighted attack rate (P = 0.02) on DCP relative to placebo were significant. Fifteen preferred DCP, one placebo and five their baseline medication.

Acetazolamide proved to improve muscle strength in eight participants with HypoPP in one other study and pinacidil, a potassium channel opener, also improved muscle strength in 2/4 participants with HypoPP in a third study.

Authors’ conclusions

The largest included study that met our inclusion criteria suggested that DCP was effective in the prevention of episodic weakness in both hypokalemic and hyperkalemic periodic paralyses. The other two studies provide some evidence that either acetazolamide or pinacidil may improve muscle strength. However we still lack sufficient evidence to provide full guidelines for the treatment of people with periodic paralysis.

**Plain Language Summary**

**Treatment for periodic paralysis**

Muscle weakness and attacks of paralysis are two important features of periodic paralyses. Paralytic attacks occur in acute episodes and can be incapacitating. Attacks may last from several hours to several days according to the type of muscle channel involved. In some cases permanent muscle weakness can also occur. We are unsure whether such permanent muscle weakness is more likely to develop if the frequency of attacks is high and therefore might be less likely to occur if attacks are fully prevented by treatment. Although the treatment of choice in periodic paralysis is generally considered to be acetazolamide, there is no standardised treatment regimen and no consensus as to when to start treatment. We do not know if acetazolamide treatment prevents any permanent weakness that may occur.

We found two small studies demonstrating an improvement of muscle strength with pinacidil and acetazolamide. There was only one trial considering treatment of paralytic attacks, demonstrating a decrease in the severity and frequency of the attacks using diclofenacamide.

We did not find other randomised or quasi-randomised studies, but only case reports and anecdotal articles using other drugs to reduce paralyses attacks. Further research is needed to determine the best treatment for reducing the frequency and severity of attacks and to treat or prevent permanent muscle weakness.

**Background**

The primary periodic paralyses (PP) are rare muscle diseases (estimated population prevalence of one per 100,000) affecting males and females of all ages, characterised by episodes of flaccid paresis affecting one or more limbs. They result from genetic disorders of ion channels called “channelopathies”.

Hypokalemic periodic paralysis (HypoPP) is caused in 80% of cases by point mutations in the voltage-gated calcium channel gene on chromosome 1 (Fontaine 1994; Jurkat-Rott 1994; Ptacek 1994b; Rojas 1991). So far, three calcium channel mutations have been described (Arg528His, Arg1239His, Arg1239Gly). HypoPP gene may also be due to a gain-of function on the voltage-gated sodium channel on chromosome 17 (Arg 672His/Gly/Ser, Arg669His) (Jurkat-Rott 2000; Sternberg 2001).

Hyperkalemic periodic paralysis (HyperPP) is caused by point mutations in the voltage-gated sodium channel on chromosome 17 (Fontaine 1990; Ptacek 1991). Sodium channelopathies include not just hyperkalemic periodic paralysis but also paramyotonia congenita, potassium-aggravated myotonia, (McClatchey 1992; Ptacek 1991; Ptacek 1992; Heine 1993). So far, about 30 point mutations in the sodium channel gene have been described.

Andersen-Tawil syndrome (ATS) is another primary periodic paralysis characterised by episodes of flaccid weakness in the context of normal, low or high serum potassium levels, sometimes with severe cardiac arrhythmias, including long QT syndrome, and skeletal and facial dysmorphic features (Andersen 1971; Sansone 1997; Tawil 1994). Mutations in the potassium channel gene KCNJ2, are the primary cause of ATS. Twenty-one mutations have been found in 30 families and have been found to cause the...
developmental, cardiac and muscle episodic electrical phenotypes of the syndrome (Plaster 2001). Functional and clinical characterisation of mutations on chromosome 17 on the KCNJ2 gene results in a loss or suppression of the function of the channel Kir2.1, which is an inward rectifier, have been associated with LQT7 (Tristani-Firouzi 2002). These mutations result in a reduction of the function of the channel (Bendahhou 2003; Donaldson 2004).

Diagnostic criteria for primary periodic paralyses have been proposed by an expert committee at the 87th European Neuromuscular Centre (ENMC) International Workshop in 2000 (Table 1; Table 2). These included mainly clinical criteria (evidence of flaccid paresis affecting one or more limbs with absent deep tendon reflexes during an attack with the typical classical profile of triggers, age at onset, duration of the attack, positive family history, response to potassium intake) and laboratory confirmation of potassium fluctuation (decrease or increase) during the attack. Additional criteria were exclusion of other secondary causes of hyper- or hypokalemia and the decremental response of the compound muscle potential after repetitive stimulation (McManis 1986). Serum potassium is normal between attacks.

In addition to the attacks of weakness, periodic paralysis may be characterised by permanent muscle weakness and a limb-girdle myopathy may develop over time (Dalakas 1983; Links 1990). It is unclear whether this is directly related to the frequency and severity of the episodes of flaccid weakness which result in cumulative damage to the muscle fibers (Dalakas 1983; Links 1990).

Evidence that potassium intake reduces the severity and frequency of the attacks of weakness in the hypokalemic periodic paralysis, has long been known. However, even regular potassium intake may fail to prevent attacks and escalating use of potassium may cause gastrointestinal problems. Nonetheless, the serum potassium abnormalities in the PP and the response to potassium administration, provided a rationale for the utilisation of drugs capable of affecting serum potassium levels, such as the carbonic anhydrase inhibitors (Griggs 1970; Links 1988).

Acetazolamide is the most commonly used of the carbonic anhydrase inhibitors, based on the results of non-randomised, single-blind trials in hypokalemic periodic paralysis (Griggs 1970; Ptacek 1994a; Resnick 1968). Dichlorphenamide (DCP) is an alternative carbonic anhydrase inhibitor (Dalakas 1983) with similar but milder side effects compared with acetazolamide. In general, studies have aimed to show a reduction in the frequency and severity of the attacks using these drugs (Bendahhou 2001; Griggs 1970; Links 1988; Links 1994). Gastrointestinal disturbances (anorexia, nausea and vomiting), drowsiness, paraesthesias, and electrolyte imbalance are the most common long term side effects of carbonic anhydrase inhibitors. Use of steroids and furosemide, during treatment with carbonic anhydrase inhibitors, may precipitate side effects.

Alternative treatments in hyperkalemic periodic paralysis have included reduction of potassium levels either by reducing intake (Dalakas 1983; Links 1988) or the use of diuretics such as hydrochlorothiazide (Links 1994; Ricker 1983).

The molecular genetic and cellular electrophysiological progress in the skeletal muscle channelopathies has been significant. Despite this biomolecular progress, effective treatment options are limited. The evidence for current treatments for the periodic paralyses is limited and thus there is no agreed consensus on treatment for PP. There continues to be debate as to the best therapy both in terms of efficacy and side effect profile. More important, given the possibility that unrecognised or untreated attacks of periodic paralysis may contribute to the appearance of permanent muscle weakness in later life, there are no data on preventive treatment, the best time to start such treatment, or the treatment of the limb-girdle myopathy if it has already occurred.

OBJECTIVES

The objective of this review is to systematically review treatment of periodic paralyses.

METHODS

Criteria for considering studies for this review

Types of studies

We included all the randomised controlled studies (including crossover studies) and quasi randomised trials in which any form of treatment for primary periodic paralysis was compared with placebo or another therapy. Open trials and single case studies have been included in the discussion, but not in the review.

Types of participants

We included all participants with a primary periodic paralyses diagnosed according to defined criteria of the ENMC International Workshop for Periodic Paralysis (unpublished data).
Types of interventions
We included any treatment for periodic paralysis including drugs, alternative therapies and physical therapies.

Types of outcome measures

Primary outcomes
Our primary outcome measure was the reduction in attack severity or frequency after at least eight weeks of treatment.

Secondary outcomes
The following secondary outcome measures were considered as defined by our initial protocol:
1. Change in muscle strength determined with manual muscle strength testing according to the 5-point Medical Research Council (MRC) scale or by dynamometric strength testing after at least eight weeks of treatment.
2. Change in muscle mass, determined by dual energy x-ray absorptiometry (DEXA) after at least eight weeks of treatment.
3. Change in Quality of Life, measured with Short Form 36 (SF36) or similar after at least eight weeks of treatment.
5. Adverse effects occurring by eight weeks of treatment excluding those events considered likely to have been induced by the withdrawal of drugs used prior to entering the study.

Search methods for identification of studies

Electronic searches
We searched the Cochrane Neuromuscular Disease Group Trials Register, MEDLINE (from January 1966 to July 2007), and EMBASE (from January 1980 to July 2007) for randomised trials and any other available international medical library sources from the University of Milan using the terms ‘periodic paralysis’, ‘hypokalemic periodic paralysis’, ‘hyperkalemic periodic paralysis’, ‘normokalemic periodic paralysis’, Andersen’s syndrome, Andersen-Tawil syndrome, periodic paralysis and cardiac arrhythmias’ as the search terms. We reviewed the bibliographies of the randomised controlled trials identified.

See Appendix 1 and Appendix 2 for MEDLINE and EMBASE strategies.

Data collection and analysis

Selection of studies
Three authors (VS, MP and TL) independently screened the abstracts of potential trials retrieved from the searches. After reading the abstracts, the papers of those studies that appeared to meet the review inclusion criteria were obtained. These papers were then read in detail and an inclusion/exclusion criteria form was completed. All the authors were in agreement with the selection of studies for inclusion in this review.

Data extraction and management
Three authors independently extracted the data of the studies onto a data extraction form.

Assessment of risk of bias in included studies
We assessed the quality of each study in terms of explicit inclusion and exclusion criteria, explicit outcome measures, secure method of randomisation, concealment of allocation, observer and participant blinding, completeness of follow-up and intention to treat analysis. Each aspect was graded with the following scale:
A: adequate
B: unclear
C: inadequate
D: not done

Data synthesis
If the data extracted had been sufficiently similar and of sufficient quality, statistical analyses would have been performed using the Review Manager 4.2 software. We would have expressed the results as mean difference and 95% confidence intervals for continuous data had the mean values of the outcomes, the standard deviations of the outcomes and the number of participants on whom the outcome was assessed in both the treated group and placebo been available in detail. However, although four studies were selected that met our inclusion/exclusion criteria these did not have overlapping patient groups or outcome measures thus limiting data analysis.

RESULTS

Description of studies
See: Characteristics of included studies; Characteristics of excluded studies.
The searches found a total of 539 papers. However there were many duplicated papers from different databases. Many were papers considering treatment in secondary periodic paralysis and were therefore excluded. Other papers were reviews and did not report on clinical trials. Seventeen papers remained. Of the 17 articles remaining, 11 were case reports, six were clinical trials. Of the articles reporting clinical trials, we excluded all the studies that were not randomised, and that did not fit the criteria for considering the study in this review leaving just three papers reporting four studies. Of these four studies, two (Ligtenberg 1996; Links 1988) did not include our primary outcome measure having no data on the reduction, if any, in the frequency and severity of attacks. They reported change in muscle strength, which was one of the secondary outcomes for our review, and demonstrated an improvement in muscle strength with acetazolamide (Links 1988) and pinacidil (Ligtenberg 1996).

The third publication (Tawil 2000), described two multicentre randomised, double blind, placebo-controlled cross-over trials: one involving 42 participants with HypoPP, and the other involving 31 participants with HyperPP. In each trial, two eight-week treatment periods were separated by a washout period of at least nine weeks; participants were their own controls. Patients were randomised to Dichlorphenamidine (DCP) or placebo in the first eight-week period, then they were crossed to the other medication after the wash out period, for another eight-week period.

The primary outcome variable in the HypoPP trial was the occurrence of an intolerable increase in attack frequency or severity, necessitating withdrawal from the treatment phase. This end point could occur at any time during a nine-week phase, and was distinguished from participant withdrawal or dropout because of adverse effects or other reasons. Secondary outcomes included 1) the average number of attacks per week over the final eight weeks of each phase, 2) the severity-weighted attack rate (calculated by averaging the severity grades for each attack per week over the 8-week period) and, 3) the participants’ preferred treatment.

The primary outcome variable in the HyperPP trial was the attack rate (average number of attacks per week over the final eight weeks of each phase). Secondary outcomes were: 1) severity-weighted attack rate and, 2) the participants’ preferred treatment.

### Risk of bias in included studies

The methodological quality of the included studies was adequate in all the aspects considered, except for drop out rates (see Table 3). Periodic paralyses are rare diseases so that a placebo-controlled crossover design as that created in the studies by Tawil and coworkers was necessary to create a parallel group in the study design. The Tawil trials were randomised with a computer-generated randomisation plan by using VAX-11 Fortran, one for each diagnostic group, which included stratification by site and blocking to ensure that each site had approximately the same number of participants assigned to each treatment sequences. At the baseline, there were no significant differences between the groups, in terms of number of participants, age, mean attack rate per week and number receiving prophylactic treatment. The number of participants who completed both treatment phases were 34/42 (81%) for the HypoPP trial and 24/31 (77.4%) for the HyperPP trial. The trials by Links 1988; and Ligtenberg 1996 were described as randomised but the method of randomisation was not given. No drop-outs were recorded in either of these two studies.

### Effects of interventions

The results of our search found four eligible studies.

The paper by Tawil 2000 reported two trials: a trial of 42 subjects HypoPP and a trial of 31 subjects with HyperPP both using dichlorphenamide (DCP). A third trial used acetazolamide in eight subjects with HypoPP (Links 1988), while a fourth used perindopril in four subjects with HypoPP (Ligtenberg 1996).

### HypoPP

In the HypoPP trial by Tawil 2000 42 HypoPP patients were enrolled with 22 assigned to the placebo/DCP sequence, and 20 to the DCP/placebo sequence. Thirty-four of 42 participants completed both treatment phases. Eight participants withdrew from the trial: three dropped out in the first phase of run-in; two dropped out in the first nine-week wash out period; three dropped out in the last eight-week treatment phase. Of these last three participants two were on DCP and they dropped out due to adverse effects, and the other one was taking placebo and was lost to follow-up. Of the 34 participants who remained, 15 reached the end point of an intolerable increase in attack frequency or severity. Of the 13 patients who exhibited a preference, 11 reached the end point while taking placebo and two while taking DCP.

For the 34 participants having attack rate data while on DCP, the mean improvement in attack rate on DCP relative to placebo was statistically significant (P = 0.02). The mean improvement in severity-weighted attack rate was statistically significant (P = 0.01) on DCP relative to placebo. Fifteen of the 34 participants reached the end point in at least one of the treatment phases. When these were included in the analyses, the statistical significance of the treatment became more evident (P = 0.001 for attack rate, P = 0.007 for severity-weighted attack rate).

When asked in a blinded fashion at the end of trial what treatment they preferred, 15 preferred DCP, three placebo and six their baseline medication, acetazolamide (see Table 4). Most of the reported adverse events were those commonly associated with carbonic anhydrase inhibitors. The most common
symptoms were confusion, difficulty with memory, difficulty concentrating, irritability, and depression. These adverse events accounted for the two dropouts related to medication side effects (dizziness, difficulty in concentration).

The trials by Links 1988 and Ligtenberg 1996 were short term studies focusing on the effects of acetazolamide and pinacidil on muscle strength and they did not assess the effects of these drugs on attack frequency or severity. In the trial by Links 1988 eight subjects with HyperPP were enrolled in a double blind cross over study with acetazolamide (125 mg x 3 daily) or placebo being given for two weeks each. Muscle strength was measured in 11 muscle groups (hip adductors, hip flexors, knee extensors, knee flexors, shoulder abductors, elbow extensors, elbow flexors, wrist extensors, 3 point grip, neck extensors, and neck flexors) with a hand-held dynamometer every week and improved significantly in seven of eight participants. The mean strength during treatment weeks was significantly greater than during placebo weeks in all participants (P = 0.05). Total muscle strength increased during the second acetazolamide week (mean increase: 10%). Surface EMG measurement performed before and after treatment showed no change in the muscle fiber conduction velocity or power spectra. One participant withdrew from the study because of side effects of dizziness, nausea and tearfulness. In one other placebo controlled double blind study (Ligtenberg 1996) of four participants with HyperPP, two showed improvement of muscle strength with pinacidil. Strength was measured using hand held myometer in four muscles (bilateral hip abductors and knee flexors) and was measured hourly during the three hour study period.

**HyperPP**

31 participants were enrolled: 15 assigned to the placebo/DCP sequence, and 16 to the DCP/placebo sequence. Twenty-four of 31 participants completed both treatment phases. Seven participants withdrew from the trial: one was lost to follow-up in the run-in phase; two dropped out in the first nine-week wash out period, three participants dropped out in the first last eight-week treatment phase. Of these last three participants, two were in DCP, and the other one was taking placebo and was lost to follow-up. One subject dropped out in the last eight-week treatment phase, in DCP for adverse effects. Sixteen patients of 24 provided attack rate data for both treatment phases: the mean improvement in attack rate on DCP relative to placebo was significant (P = 0.006), and the mean improvement in severity-weighted attack rate on DCP relative to placebo was also significant (P = 0.02).

When asked in a blinded fashion at the end of trial what treatment they preferred, 15 preferred DCP, one placebo and five their baseline medication (see Table 5).

The adverse effects in this group were similar to those observed in the HypoPP trial. One participant dropped out of the study because of adverse events (dizziness, difficulty concentrating at work) while taking DCP.

**DISCUSSION**

The finding of only two randomised controlled trials in the literature focusing on attack frequency and severity, implies that despite advances in molecular biology and cell physiology in the field of skeletal channelopathies, there is still a huge gap between our scientific knowledge and any evidence base for treatment strategies in PP. Studies on treatment strategies have been limited in the periodic paralyses probably due to the relatively 'benign' nature of the disorders because of the transitory nature of the paralytic episodes. However, increasing reports on the development of a limb-girdle myopathy show that some people with periodic paralysis may be as disabled as others with muscular dystrophies. The paucity of literature data on treatment in the periodic paralyses may also reflect the difficulties in constructing a trial in this group of disorders: the drop out rate may be exceedingly high to render a trial acceptable. Consider the Tawil trial in which there was nearly one fifth and one fourth, respectively in HyperPP and HypoPP, of drop out rate.

The study by Tawil and coworkers demonstrates the efficacy of DCP in reducing the frequency and severity of episodic weakness in PP. It shows that attack rates were significantly lower during the DCP phase than during the placebo phase in both the HypoPP and the HyperPP trials and that 17 of the 34 participants had to stop the placebo phase because the attack rate was intolerable. However, the clinical details of these participants were insufficient to identify a specific profile.

Previous studies with acetazolamide were single blind (Resnick 1968; Griggs 1970) or case reports (Raphael 1977) and were thus not considered in our data analysis. However, all suggested a beneficial effect of acetazolamide in reducing the frequency of attacks. The study by Tawil and workers did not address relative efficacy of acetazolamide versus dichlorphenamide although many patients were on acetazolamide before entering the study. A carry-over effect was minimised in the study by Tawil and coworkers given the short half-life of acetazolamide. We have analysed other studies which have looked at the reduction of attack frequency and these have included several drugs in either hypokalemic periodic paralysis or hyperkalemic periodic paralysis (see tables for studies included and excluded in the review). (i) nine participants with HypoPP were treated with Verapamil in a double blind trial (Links 1998). A positive effect with verapamil was not excluded; (ii) one participant with Hyper PP with metaprotenol (Bendheim 1985), salbutamol (Hanna 1998; Wang 1976), DCP (Sander 1988); (iii) Verapamil and diazoxide are described in two clinical trials (Links 1998; Johnsen 1977b) to reduce the number of attacks in people with HypoPP. A trial on four participants with
HypoPP (Johnsen 1977b) indicated no benefit in treatment with propranolol. Lithium did not seem to be beneficial in one participant with HyperPP (Pope 1984). These studies were small non-randomised trials that did not in themselves offer certain alternative treatment options to acetazolamide or DCP.

When considering Andersen-Tawil syndrome still less information is available on treatment for the paralytic events (Djurhuus 1998; Junker 2002) so that no evidence based treatment can be recommended for this variety of periodic paralysis.

When considering muscle weakness and the potential limb-girdle myopathy that may be present in some of these people, still less information is available to define guidelines for preventive treatments. There are only a few studies with dichlorphenamide (Dalakas 1983; Links 1988), using a single-blind, placebo-controlled design, aimed at the prevention of persistent interattack weakness. These studies provide encouraging results on the use of dichlorphenamide or acetazolamide. The number of participants in these studies is however limited and despite clinical evidence the lack of genetic characterisation at the time represents a limitation to the interpretation of the results. This same limitation characterises another study with a potassium-channel opener, pinacidil. Ligtenberg and coworkers (Ligtenberg 1996), demonstrated an improvement in muscle strength in four people with hypokalemic periodic paralysis during attacks provoked with hyperglycemic glucose clamp. Although encouraging these studies were too small and anecdotal. Although the carbonic acid anhydrase inhibitors are the current treatment options in HyperPP and HypoPP, further studies on a larger number of participants in multicentre studies are needed to define which drug is best for both periodic and interictal weakness comparing efficacy, side-effects and cost-benefits in the primary periodic paralyses. However there is insufficient information to say which of the carbonic acid anhydride inhibitors (dichlorphenamide or acetazolamide) is more efficacious or has fewer side effects. If dichlorphenamide proves to be more efficacious than acetazolamide, as suggested by the study by Tawil, it is worth noting that the drug has been withdrawn by the manufacturers, except in Italy, for reasons other than safety and effectiveness. The best treatment for permanent muscle weakness in periodic paralysis has not been evaluated in any randomised trial. It is yet unclear whether attack frequency leads to permanent muscle weakness or whether reducing the attacks prevents this progression. The best treatment for attack frequency or permanent muscle weakness in the periodic paralysis associated with Andersen-Tawil syndrome has not been evaluated in any trial. In particular, in these forms of periodic paralysis treatment options are limited by the potential effects on the cardiac conduction system, which may be severely involved in Andersen-Tawil Syndrome.

**Implications for research**

Further research is needed to determine (i) if carbonic acid anhydrase inhibitors are indeed beneficial and if dichlorphenamide is better than acetazolamide when considering cost-benefit effects and side-effects; (ii) if permanent muscle weakness may be prevented or partially treated by these drugs; (iii) if specific mutations respond better than others with these drugs when considering both attack frequency and severity and permanent muscle weakness; (iv) if attacks of paralysis in Andersen-Tawil syndrome respond to the same drugs as the other primary periodic paralysis especially considering potential effects on the cardiac conduction system resulting from the electrolyte imbalance; (v) if treatment should start early in the disease course, no matter what the rate or severity of attacks, and if this approach could reduce the risk of developing a permanent myopathy.

**Authors’ conclusions**

**Implications for practice**

In clinical practice a single double-blind randomised placebo-controlled cross-over trial and case reports on a limited number of participants suggest that carbonic acid anhydrase inhibitors reduce attack frequency and severity in the primary periodic paralyses. However there is insufficient information to say which of the carbonic acid anhydride inhibitors (dichlorphenamide or acetazolamide) is more efficacious or has fewer side effects. If dichlorphenamide proves to be more efficacious than acetazolamide, as suggested by the study by Tawil, it is worth noting that the drug has been withdrawn by the manufacturers, except in Italy, for reasons other than safety and effectiveness. The best treatment for permanent muscle weakness in periodic paralysis has not been evaluated in any randomised trial. It is yet unclear whether attack frequency leads to permanent muscle weakness or whether reducing the attacks prevents this progression. The best treatment for attack frequency or permanent muscle weakness in the periodic paralysis associated with Andersen-Tawil syndrome has not been evaluated in any trial. In particular, in these forms of periodic paralysis treatment options are limited by the potential effects on the cardiac conduction system, which may be severely involved in Andersen-Tawil Syndrome.

**Acknowledgements**

We are particularly grateful to Kate Jewitt for continuous support in writing the review and providing additional technical information with the Cochrane review system.
References to studies included in this review

Ligtenberg 1996  [published data only]

Links 1988  [published data only]

Tawl 2000  [published and unpublished data]

References to studies excluded from this review

Bendheim 1985  [published data only]

Brillman 1973  [published data only]

Confavreux 1991  [published data only]

Dalakas 1983  [published data only]

Djurhuus 1998  [published data only]

Griggs 1983  [published data only]

Hanna 1998  [published data only]

Ikeda 2002  [published data only]

Johnsen 1977a  [published data only]

Johnsen 1977b  [published data only]

Junker 2002  [published data only]

Links 1994  [published data only]

Links 1998  [published data only]

Meola 2000  [published data only]

Pope 1984  [published data only]

Raphael 1977  [published data only]

Riggs 1981  [published data only]

Sander 1988  [published data only]
Streib 1985  (published data only)

Thompson 1984  (published data only)

Torres 1981  (published data only)

Vern 1987  (published data only)

Wang 1976  (published data only)

Additional references

Andersen 1971

Bendahhou 2001

Bendahhou 2003

Donaldson 2004

Fontaine 1990

Fontaine 1994

Griggs 1970

Heine 1993

Jurkat-Rott 1994

Jurkat-Rott 2000

Links 1990

McClatchey 1992

McManis 1986

Plaster 2001

Ptacek 1991

Ptacek 1992

Ptacek 1994a

Ptacek 1994b

**Resnick 1968**

**Ricker 1983**

**Rojas 1991**

**Sansone 1997**

**Sternberg 2001**

**Tawil 1994**

**Tristani-Firouzi 2002**

* Indicates the major publication for the study
## Characteristics of included studies

### Ligtenberg 1996

<table>
<thead>
<tr>
<th>Methods</th>
<th>Randomised, double blind, placebo-controlled.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>4 participants with HypoPP, 8 matched controlled subjects.</td>
</tr>
<tr>
<td>Interventions</td>
<td>Pinacidil vs Placebo</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Insulin sensitivity during hyperglycemic glucose clamp. Improvement in muscle strength</td>
</tr>
</tbody>
</table>

### Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors' judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Yes</td>
<td>A - Adequate</td>
</tr>
</tbody>
</table>

### Links 1988

<table>
<thead>
<tr>
<th>Methods</th>
<th>Randomised, double blind, placebo-controlled cross-over trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>8 participants with HypoPP.</td>
</tr>
<tr>
<td>Interventions</td>
<td>ACZ vs Placebo</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Improvement in muscle strength</td>
</tr>
</tbody>
</table>

### Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors' judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Yes</td>
<td>A - Adequate</td>
</tr>
</tbody>
</table>

### Tawil 2000

<table>
<thead>
<tr>
<th>Methods</th>
<th>Multicentre, randomised, double-blind, placebo-controlled, cross-over trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>42 participants with Hypokalemic Periodic Paralysis. 31 Hyperkalemic Periodic Paralysis.</td>
</tr>
<tr>
<td>Interventions</td>
<td>DCP vs placebo</td>
</tr>
</tbody>
</table>

### Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors' judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Yes</td>
<td>A - Adequate</td>
</tr>
</tbody>
</table>
Outcomes

HypoPP: the primary outcome was the occurrence of an intolerable increase in attack frequency or severity, necessitating withdrawal from the treatment phase; a secondary outcome was the average number of attacks per week over the final 8 weeks of each phase. HyperPP: the primary outcome variable was the average number of attacks per week over the final 8 weeks of each phase; other secondary outcome variables were severity-weighted attack rate and the preferred treatment.

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors' judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Yes</td>
<td>A - Adequate</td>
</tr>
</tbody>
</table>

Characteristics of excluded studies  [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bendheim 1985</td>
<td>Case report only</td>
</tr>
<tr>
<td>Brillman 1973</td>
<td>Case report only</td>
</tr>
<tr>
<td>Confavreux 1991</td>
<td>Case report only</td>
</tr>
<tr>
<td>Dalakas 1983</td>
<td>Placebo-controlled case report. Not randomised and/or double blind</td>
</tr>
<tr>
<td>Djurhuus 1998</td>
<td>Case report only</td>
</tr>
<tr>
<td>Griggs 1983</td>
<td>Case report only</td>
</tr>
<tr>
<td>Hanna 1998</td>
<td>Case report only</td>
</tr>
<tr>
<td>Ikeda 2002</td>
<td>Case report only</td>
</tr>
<tr>
<td>Johnsen 1977a</td>
<td>No randomisation</td>
</tr>
<tr>
<td>Johnsen 1977b</td>
<td>No randomisation</td>
</tr>
<tr>
<td>Junker 2002</td>
<td>Case report only</td>
</tr>
<tr>
<td>Links 1994</td>
<td>Case report only</td>
</tr>
<tr>
<td>Links 1998</td>
<td>Observational study only</td>
</tr>
</tbody>
</table>
(Continued)

<table>
<thead>
<tr>
<th>Reference</th>
<th>Type of Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meola 2000</td>
<td>Case report only</td>
</tr>
<tr>
<td>Pope 1984</td>
<td>Double blind but non-randomised trial</td>
</tr>
<tr>
<td>Raphael 1977</td>
<td>Case report only</td>
</tr>
<tr>
<td>Riggs 1981</td>
<td>Case report only</td>
</tr>
<tr>
<td>Sander 1988</td>
<td>Case report only</td>
</tr>
<tr>
<td>Streib 1985</td>
<td>Case report only</td>
</tr>
<tr>
<td>Thompson 1984</td>
<td>Case report only</td>
</tr>
<tr>
<td>Torres 1981</td>
<td>Single blind non-randomised trial</td>
</tr>
<tr>
<td>Vern 1987</td>
<td>Case report only</td>
</tr>
<tr>
<td>Wang 1976</td>
<td>No randomisation</td>
</tr>
</tbody>
</table>
## DATA AND ANALYSES

### Comparison 1. Comparison between HypoPP and HyperPP attack rate per week on DCP relative to placebo

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Mean improvement in attack rate per week on DCP relative to placebo</td>
<td>1</td>
<td>33</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>-1.4 [-2.97, 0.17]</td>
</tr>
<tr>
<td>2 Mean improvement in severity-weighted attack rate per week on DCP relative to placebo</td>
<td>1</td>
<td>33</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>-3.50 [-6.38, -0.62]</td>
</tr>
</tbody>
</table>

### Analysis 1.1. Comparison 1 Comparison between HypoPP and HyperPP attack rate per week on DCP relative to placebo, Outcome 1 Mean improvement in attack rate per week on DCP relative to placebo.

Review: Treatment for periodic paralysis

Comparison: 1 Comparison between HypoPP and HyperPP attack rate per week on DCP relative to placebo

Outcome: 1 Mean improvement in attack rate per week on DCP relative to placebo

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>HypoPP</th>
<th>HyperPP</th>
<th>Mean Difference</th>
<th>Weight</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N Mean(SD)</td>
<td>N Mean(SD)</td>
<td>IV(Fixed,95% CI)</td>
<td></td>
<td>IV(Fixed,95% CI)</td>
</tr>
<tr>
<td>Tawil 2000</td>
<td>17 0.9 (1.4)</td>
<td>16 2.3 (2.9)</td>
<td>-1.40 [ -2.97, 0.17 ]</td>
<td>100.0 %</td>
<td>-1.40 [ -2.97, 0.17 ]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>17</td>
<td>16</td>
<td></td>
<td>100.0 %</td>
<td>-1.40 [ -2.97, 0.17 ]</td>
</tr>
</tbody>
</table>

Heterogeneity: not applicable

Test for overall effect: Z = 1.75 (P = 0.080)

Test for subgroup differences: Not applicable
**Analysis 1.2. Comparison 1** Comparison between HypoPP and HyperPP attack rate per week on DCP relative to placebo, Outcome 2 Mean improvement in severity-weighted attack rate per week on DCP relative to placebo.

Review: Treatment for periodic paralysis

Comparison: 1 Comparison between HypoPP and HyperPP attack rate per week on DCP relative to placebo

Outcome: 2 Mean improvement in severity-weighted attack rate per week on DCP relative to placebo

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>HypoPP</th>
<th>HyperPP</th>
<th>Mean Difference</th>
<th>Weight</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>17</td>
<td>16</td>
<td></td>
<td>100.0%</td>
<td>-3.50 [-6.38, -0.62]</td>
</tr>
<tr>
<td>Mean(SD)</td>
<td>1.1 (1.5)</td>
<td>4.6 (5.7)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>17</td>
<td>16</td>
<td></td>
<td>100.0%</td>
<td>-3.50 [-6.38, -0.62]</td>
</tr>
</tbody>
</table>

Heterogeneity: not applicable

Test for overall effect: Z = 2.38 (P = 0.017)

Test for subgroup differences: Not applicable

**A D D I T I O N A L  T A B L E S**

Table 1. Diagnostic criteria for primary hypokalemic periodic paralysis

<table>
<thead>
<tr>
<th>Diagnostic criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Two or more attacks of muscle weakness with documented serum K &lt; 3.5 mEq/L.</td>
</tr>
<tr>
<td>(2) One attack of muscle weakness in the proband and one attack of weakness in one relative with documented serum K &lt; 3.5 mEq/L in at least one attack</td>
</tr>
<tr>
<td>(3) Three of six clinical or laboratory features outlined below:</td>
</tr>
<tr>
<td>(a) Onset in the 1st or 2nd decade.</td>
</tr>
<tr>
<td>(b) Attack duration (muscle weakness involving one or more limbs) &gt; 2 hours.</td>
</tr>
<tr>
<td>(c) Positive triggers (high CHO rich meal, rest after exercise, stress).</td>
</tr>
<tr>
<td>(d) Improvement with potassium intake.</td>
</tr>
<tr>
<td>(e) Positive family history or genetically confirmed skeletal calcium or sodium channel mutation.</td>
</tr>
<tr>
<td>(f) Positive McManis short exercise test.</td>
</tr>
<tr>
<td>(4) Exclusion of other causes of hypokalaemia (renal, adrenal, thyroid dysfunction; renal tubular acidosis; diuretic and laxative abuse)</td>
</tr>
</tbody>
</table>
Table 2. Diagnostic criteria for primary hyperkalemic periodic paralysis

<table>
<thead>
<tr>
<th>Diagnostic criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Two or more attacks of muscle weakness with documented serum K &gt; 4.5 mEq/L</td>
</tr>
<tr>
<td>(2) One attack of muscle weakness in the proband and one attack of weakness in one relative with documented serum K &gt; 4.5 mEq/L in at least one attack</td>
</tr>
<tr>
<td>(3) Three of six clinical or laboratory features outlined below:</td>
</tr>
<tr>
<td>(a) onset &lt; 3rd decade</td>
</tr>
<tr>
<td>(b) attack duration (muscle weakness involving one or more limbs) &lt; 2 hours</td>
</tr>
<tr>
<td>(c) positive triggers (exercise, stress)</td>
</tr>
<tr>
<td>(d) myotonia</td>
</tr>
<tr>
<td>(e) positive family history or genetically confirmed skeletal sodium channel mutation</td>
</tr>
<tr>
<td>(f) positive McManis short exercise test</td>
</tr>
<tr>
<td>(4) Exclusion of other causes of hyperkalaemia (renal, adrenal, thyroid dysfunction; potassium-sparing diuretics use)</td>
</tr>
</tbody>
</table>

Table 3. Methodological quality of the included studies

<table>
<thead>
<tr>
<th>Assessment criteria</th>
<th>Evaluation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Secure method of randomisation</td>
<td>A</td>
</tr>
<tr>
<td>Allocation concealment</td>
<td>A</td>
</tr>
<tr>
<td>Blinding</td>
<td>A</td>
</tr>
<tr>
<td>Completeness of follow up</td>
<td>B</td>
</tr>
</tbody>
</table>

Table 4. Outcomes in HypoPP patients (Tawil 2000)

<table>
<thead>
<tr>
<th>Primary outcome measure: reduction in severity or frequency of attacks</th>
<th>Reduction of number of attacks per week from 2.0757 during placebo phase to 1.893 during DCP phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Secondary outcome measures: change in muscle strength</td>
<td>Not considered in this study.</td>
</tr>
<tr>
<td>Change in muscle mass (DEXA)</td>
<td>Not considered in this study.</td>
</tr>
<tr>
<td>Change in Quality of Life</td>
<td>Not considered in this study.</td>
</tr>
<tr>
<td>Preference of treatment strategy</td>
<td>15/42 pts preferred DCP; 3/42 pts preferred placebo; 6/42 preferred their baseline medication (4 were taking nothing, 1 was taking ACZ, 1 was taking DCP at baseline). Data were not determined for 18 patients</td>
</tr>
</tbody>
</table>
Table 4. Outcomes in HypoPP patients (Tawil 2000) (Continued)

| Adverse events | Most common AE were paraesthesia (42%) and cognitive symptoms (21%), responsible for 2 drop outs due to adverse events |

Table 5. Outcomes in HyperPP patients (Tawil 2000)

| Primary outcome measure: reduction in severity or frequency attacks | Reduction of number of attacks per week from 3.798 during placebo phase to 3.141 during DCP phase |
| Secondary outcome measures: change in muscle strength | Not considered in this study, |
| Change in muscle mass (DEXA) | Not considered in this study, |
| Change in Quality of Life | Not considered in this study, |
| Preference of treatment strategy | 15/31 pts preferred DCP; 1/31 pts preferred placebo; 5/31 preferred their baseline medication (4 were taking nothing, 1 was taking ACZ). Data were not determined for 10 patients |
| Adverse effects | Most common AE were paraesthesia (38%) and cognitive symptoms (24%), responsible for 1 drop out due to adverse events (memory loss) |

APPENDICES

Appendix 1. Ovid MEDLINE Search Strategy

1. exp Paralyses, Familial Periodic/
2. (paralys$ and periodic).mp.
3. (hypokalaemic or hypokalemic or hyperkalaemic or hyperkalemic).mp. [mp=title, original title, abstract, name of substance word, subject heading word]
4. 2 and 3
5. 1 or 4
6. randomized controlled trial.pt.
7. controlled clinical trial.pt.
8. randomized controlled trials/
9. random allocation/
10. double-blind method/
11. single-blind method/
12. or/6-11
13. animals/ not humans/
14. 12 not 13
15. clinical trial.pt.
16. exp clinical trials/
17. (clin$ adj25 trial$).ti,ab.
18. ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$)).ti,ab.
19. placebo/
20. placebo$.ti,ab.
21. random$.ti,ab.
22. research design/
23. or/15-22
24. 23 not 13
25. 24 not 14
26. comparative study/
27. exp evaluation studies/
28. follow up studies/
29. prospective studies/
30. (control$ or prospectiv$ or volunteer$).ti,ab.
31. or/26-30
32. 31 not 13
33. 32 not (14 or 25)
34. 14 or 25 or 33
35. 5 and 34
36. Andersen's Syndrome
37. Andersen-Tawil Syndrome and treatment or therapy
38. normokalemic periodic paralysis and treatment or therapy
39. Periodic paralysis and cardiac arrhythmias and treatment or therapy

**Appendix 2. Ovid EMBASE Search Strategy**

1. exp Periodic Paralysis/
2. (paralys$ and periodic).mp.
3. (hypokalaemic or hypokalemic or hyperkalaemic or hyperkalemic).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]
4. 2 and 3
5. 1 or 4
6. Randomized Controlled Trial/
7. Clinical Trial/
8. Multicenter Study/
9. Controlled Study/
10. Crossover Procedure/
11. Double Blind Procedure/
12. Single Blind Procedure/
13. exp RANDOMIZATION/
14. Major Clinical Study/
15. PLACEBO/
16. Meta Analysis/
17. phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical trial/
19. ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$)).tw.
20. placebo$.tw.
21. random$.tw.
22. control$.tw.
23. (meta?analys$ or systematic review$).tw.
WHAT'S NEW

Last assessed as up-to-date: 13 November 2007.

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>27 April 2008</td>
<td>Amended</td>
<td>Converted to new review format.</td>
</tr>
</tbody>
</table>

HISTORY

Protocol first published: Issue 3, 2004
Review first published: Issue 1, 2008

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>14 November 2007</td>
<td>New citation required and conclusions have changed</td>
<td>Substantive amendment</td>
</tr>
</tbody>
</table>

CONTRIBUTIONS OF AUTHORS

Valeria Sansone and Marta Panzeri wrote the review. Thera Links reviewed the papers together with Valeria Sansone and Marta Panzieri. Michael Rose helped with data analysis. Giovanni Meola and all other authors revised and discussed the paper.
DECLARATIONS OF INTEREST

Doctors Sansone, Panzeri, Links and Meola are involved in the NIH-funded grant on acetazolamide versus dichlorphenamide in periodic paralyses.

INDEX TERMS

Medical Subject Headings (MeSH)

Acetazolamide [therapeutic use]; Carbonic Anhydrase Inhibitors [therapeutic use]; Dichlorphenamide [therapeutic use]; Hypokalemic Periodic Paralysis [∗ drug therapy]; Paralysis, Hyperkalemic Periodic [∗ drug therapy]; Pinacidil [therapeutic use]; Randomized Controlled Trials as Topic

MeSH check words

Humans